Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients

Instituto Venezolano de Investigaciones Cientificas

Status and phase: Completed; Phase 3; Phase 2

Conditions: COVID-19; COVID-19 Respiratory Infection; COVID-19 Pneumonia; COVID-19 Acute Respiratory Distress Syndrome; COVID-19 Lower Respiratory Infection

Treatments: Drug: Carvacrol; Other: Control group

Study type: Interventional

Funder types: Other

Identifiers

NCT05445089

LAB-2020-01

ISRCTN registry (Registry Identifier)

Details and patient eligibility

About

• Check the efficacy, safety and tolerability of the compound Modified isothymol against the SARS-CoV-2 agent in patients COVID-19.

Full description

• Evaluate the inhibition of the terminal glycosylation of the Enzyme Angiotensin II converter (ECE2).
• Check the inhibition of the main protease function (Mpro) of the SARS-CoV-2 agent by stable binding of the drug/protein to control viral replication.
• Check the oxidation reaction of the amine R-CH2-NH2 involved in the hyperactivation of macrophages (immune system innate), by interference of modified Isothymol.
• Evaluate the increase in tolerance to hypersensitivity of the immunoglobulins G (IgG) and immunoglobulins M (IgM) in patients COVID-19.
• Check the suppression of production and adhesion of superoxides in neutrophils (Immunostimulatory effect) through the regulation of cytokines and IL-6 (interleukins) for the inhibition of cytokine storm (Stage 2 and 3, infected patient).

Enrollment: 600 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

The study population will be patients aged ≥18 years with RT-PCR positive (detection of genetic material from SARS-CoV-2 in the analyzed sample), eligible for COVID-19, who attend a center physician with an active primary care program, in the early hours from the onset of symptoms. In the case of asymptomatic the analysis of the nasopharyngeal swab will be verified in the triage, and in Depending on the result, they may or may not be included in the clinical protocol.

A sample size of 600 patients is expected, which must be randomize for parallel administration of experimental drug (300 patients) and placebo (300 patients).

It should be evaluated prior to the start of the clinical trial: Tests of rapid diagnosis (PDR test), chain reaction of the Reverse Transcriptase Polymerase (RT-PCR test), pressure blood pressure, pulse, temperature, body weight, blood tests, detection of autoimmune and infectious diseases (HIV, lupus, rheumatoid arthritis, hepatitis, syphilis), detection of antibodies (immunoglobulin G and immunoglobulin and M), urine tests for detect drugs and pregnancy (in the case of women) and other comorbid conditions characterized. In addition, chest x-ray should be performed on each patient included in the test, and if possible perform a computerized tomography (before and after treatment with modified Isothymol).

There will be an electronic system to load all the variables scientific and clinical protocol established in data collection, and will also allow processing of expedited output variables, which can be audited in real time.

Participant inclusion criteria:

1. Positive test PDR, positive test RT-PCR, patients diagnosed with COVID-19
2. Chest pain or other symptom consistent with bilateral pneumonia atypical, with one of the following paraclinical alterations and imaging:
3. Oxygen saturation (SpO2) ≤93%.
4. Elevation of D-dimer ≥10 mg/mL.
5. Elevation of Ferritin ≥120 ng/mL.
6. Elevation of Fibrinogen ≥400 mg/dL
7. Elevation of Immunoglobulin M (IgM) ≥200 mg/dL.
8. Elevation of Interleukin 6 (IL-6) ≥1800 pg/mL.
9. Rx. chest and CT showing thickening of the bronchi, consolidation and ground glass opacities.

Participant exclusion criteria:

Negative test PDR, negative test RT-PCR and Inadequate administration of antiviral (for non-compliance with indicated intervals or death of the patient before 15 days treatment indications).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

600 participants in 2 patient groups, including a placebo group

Isothymol or Carvacrol group

Experimental group

Description:

* Each ml contains 6mg of Isothymol or Carvacrol (2-Methyl-5-(1-methylethyl)-phenol modified) at 1% v/v. (GRAS lipophilic modified with isothymol). * Oral solution (dispersion L/L). Dilute lipophilic aqueous solution of light or medium yellow. * Excipients: Cis-9-octadecenoic acid with Squalene (99%).

Treatment:

Drug: Carvacrol

Control

Placebo Comparator group

Description:

•Placebo

Treatment:

Other: Control group